GlassScriptPhysician profile
Basma Al Mandil
NPI 1922292093
$10,513.83
in general payments reported to CMS, 2019-2025
44 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,650 · 2020: $637 · 2021: $1,099 · 2022: $1,936 · 2023: $2,206 · 2024: $1,261 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,091 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,091.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,551.60 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,329.56 | 2019-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $1,226.12 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $871.25 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $661.89 | 2019-2024 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.66 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Jazz Pharmaceuticals INC. | $480.29 | 2019-2025 | Xywav |
| Regeneron Healthcare Solutions, INC. | $468.68 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $400.00 | 2020-2025 | Wakix |
| Amgen INC. | $331.25 | 2022-2025 | Tezspire, Tavneos |
| Genentech USA, INC. | $236.45 | 2019-2025 | Xolair |
| Insmed, INC. | $223.56 | 2019-2025 | Arikayce |
| Grifols USA, LLC | $219.36 | 2019-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $189.09 | 2019-2020 | |
| Verona Pharma, INC. | $159.39 | 2025 | Ohtuvayre |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basma Al Mandil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.